A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors

The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced/metastatic solid tumors

Trial Details

NCT ID
NCT06848699
Phase
PHASE1 / PHASE2
Sponsor
Shanghai Henlius Biotech
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HLX43 dose 1
  • HLX43 dose 2
  • HLX43 dose 3
  • HLX43 dose 4
  • HLX43 dose 5
  • Serplulimab
Locations (sample)
  • Hunan, Changsha, China|32.92741,120.18021
  • Jinan, Shangdong, China|36.66833,116.99722
  • Chongqing, China|29.56026,106.55771

Key Eligibility Criteria

  • Voluntarily participate in the clinical trial; fully understand and be informed about this study and sign the Informed Consent Form (ICF); be willi…
  • Age at the time of signing the ICF is ≥ 18 years and ≤ 75 years;
  • Phase Ib enrollment of patients with histologically or cytologically confirmed advanced /metastatic solid tumor who have experienced treatment fail…
  • Within 4 weeks prior to the first dose, at least one measurable lesion assessed by the investigator according to RECIST 1.1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →